No profile data available.
Eloxx Pharmaceuticals, Inc. (ELOX) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Arlington, United States, with about 10 full-time employees.
It reported revenue of $0 for fiscal year 2025, down 100.0% from fiscal year 2024, and net income of -$6.00 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $55.46 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia.
Eloxx Pharmaceuticals reported $0 in revenue for fiscal year 2025, down 100.0% from $6.36 million in fiscal year 2024. In Q1 2026 revenue was $0.
$55.46 million as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Telomir Pharmaceuticals, Inc. (TELO), XBiotech Inc. (XBIT), Metagenomi, Inc. (MGX), MiNK Therapeutics, Inc. (INKT).